Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Malignant Pain Patients
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Sleep disturbance is perhaps one of the most prevalent complaints of patients with
long-standing painful conditions. Nabilone is a medication that is approved by Health Canada
as an anti-emetic (prevent vomiting) for patients undergoing chemotherapy. Nabilone, due to
its sleep promoting properties, is sometimes prescribed by physicians to pain patients to
help improve their sleep. However, there is no direct research evidence to either support or
refute this practice. This study will investigate if nabilone is effective in improving sleep
in insomnia and pain patients.
Phase:
Phase 2
Details
Lead Sponsor:
University Health Network, Toronto
Collaborators:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.